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Edward De Maeyer's question about the relevance in real life of the numerous immunoregulatory effects of inter-ferons (IFN) documented in vitro is certainly a good one, as are most questions with no definitive answer. Indeed, there seems to be no decisive demonstration that IFN have an immunoregulatory role in vivo, despite compelling convergence of indirect evidence in both man and experimental animals. Our own bias, however, is that the answer is positive, and we base this semi-rational feeling on the following arguments.
The first argument is that IFN has at least one role that has been demonstrated in vivo, and that is its participation in host defence against viruses. The finding that IFN administration in experimental animals may provide some protection against virus infection was not entirely convincing, since it did not tell about the role of endogenous IFN in recovery. Decisive evidence has come from experiments using specific antibody to IFN-~ and -~ able to neutralize endogenously produced IFN molecules. The pioneering work by B. Fauconnier [1] provided encouraging evidence, and work by I. Gresser and his colleagues [2] has shown conclusively that administration of an antiserum to mouse IFN-~/~ enhanced viral replication and potentiated the disease induced by encephalomyocarditis, herpes simplex, Moloney sarcoma, vesicular stomatitis and Newcastle disease viruses. Using the same approach, we have shown that early IFN production has a critical role in the genetically controlled resistance to mouse hepatitis virus [3] . However, whereas this type of work demonstrates an important role for IFN in vivo, it does not elucidate whether endogenous IFN protects against virus infection directly through its antiviral properties or indirectly through its ability to modify the functions of immunocompetent cells.
A second argument comes from the observation that IFN administration in patients exerts a series of effects that indicate a modification of leukocyte functions. Thus, repeated injections of leukocyte IFN cause reversible lymphopaenia and bone marrow hypoplasia [4] , and this is likely to be due to the well documented cytostatic effects of IFN on bone marrow precursor cells [5] . Similarly, IFN adminis-tration is frequently pyrogenic in patients, even when recombinant molecules are used [4] . This is reminiscent of our observation that incubation with ~-or ~-IFN of human monocytes increases the secretory potential of interleukin-1, a molecule which appears to be identical to endogenous pyrogen [6] . Clear evidence that IFN administration enhances natural killer (NK) activity has been obtained in both mice [7] and man [8] . Altogether, these observations indicate that exogenous IFN can manipulate some functions of leukocytes, but this does not necessarily imply a role of naturally produced interferons in immunoregulation.
The immunological role of endogenous IFN secretion is certainly a key point of discussion in the present debate. In this field, the most telling evidence should come from the observation that an immunological disorder may result from defective production of IFN, as is seen in some inbred mouse strains or in humans with a (( selective ), defect of secretion of one or more IFN species. In the mouse, the pattern of inbred strains with low IFN production varies according to the inducer used and the IFN species considered. It is interesting, however, to compare the genetics of IFN-7 production with that of virus-induced (~/~) IFN. Some common features appear, since BALB/c mice appear to be low producers and C57BL/6 high producers, not only for IFN-7 [9] , but also for IFN production after stimulation with Newcastle disease virus (If-1 locus) mouse mammary tumour virus (If-2 locus) and Sendai virus (If-3 and If-4 loci) [10] . A striking correlation can be found between IFN production and the ability of these two mouse strains to cope with intracellular microorganisms. Thus BALB/c mice, apart from being low producers of both virusinduced and IFN-u are opposed to C57BL mice by their increased susceptibility to many infections including listeriosis [11] and herpes simplex virus infection [12] . This is reminiscent of the known macrophage-activatingfactor (MAF) effects of interferons in vitro, and suggests that impairment in the production of the two main species of leukocyte IFN (~ and -~) leads to defective activation of the reticulo-endothelial system with a secondary defect of immunity to a range of intracellular microorganisms.
In the human, selective defects of IFN production clearly correlate with secondary immunological abnormalities which can be reversed by IFN therapy. In normal human neonates, susceptibility to infections with both viruses and intracellular microorganisms is enhanced, and this implies that T-cell immunity is impaired. No major T-cell abnormality can be substantiated, however, except for a profound defect in IFN-u secretion [13] . This is due to a special type of immunological dysregulation rather than an intrinsic defect and is associated with an increased sensitivity of IFN secretion to the suppressive effects of prostaglandins-E [14] . The relatively selective defect of at this age of life may be envisaged as a major cause of immunological dysfunction, since correction by IFN of two associated abnormalities, namely low NK activity [15] and low HLA-DR expression [16] , suggest that they are consequences rather than causes of the defect in IFN-u secretion.
In human neonates, the defective IFN concerns only IFN-7 secretion, since secretion of I'FN-~ appears to be normal. Observations in the mouse, as discussed above, suggest that defective secretion of both types of IFN of leukocyte origin (~ and y) leads to severe impairment of the host defence against a range of infections with intracellular microorganisms. For the past 10 years, we have been investigating the functioning of the IFN .system in patients with constitutional immune disorders. Apart from a complete IFN-7 defect in patients without T lymphocytes, as expected in the absence of any T-cell function, two main types of ~(selective ~ defects of IFN secretion, contrasting with the normal character of other immunological functions tested, have been observed [17] .
One is the inability of T cells to proliferate and to produce IFN-7 in response to the antigens of the intra-cellular microorganism causing persistent infection, such as BCG or salmonella. It is known that immunity against the intracellular (intra-monocyte) microorganism is based upon specific induction of lymphokines with MAF activities, able to activate macrophages for increased destruction of the microorganism. IFN-T is able to activate monocytes for interleukin-1 secretion [18] and antimicrobial immunity [19] . Whatever the exact cause of this acquired T-cell unresponsiveness to persistent microorganisms, the lack of IFN-7 (and thus of MAF) secretion appears to be critical in the persistence of the microorganism in macrophages. Since all IFN species show MAF activities, we have treated some of these patients with IFN-~r and have obtained a striking regression of infections, as described previously [20] .
The second situation is characterized by a selective defect of both IFN-~ induced by co-culture of leukocytes with lymphoblastoid cell lines and IFN-u induced by mitogens and antigens. This parallel defect contrasts with normal immune functions (antibody production, delayed hypersensitivity, T-cell markers and proliferation) and is associated with frequent, severe and persistent infections with both viruses (such as Epstein-Barr virus, adenovirus or coronavirus) and bacterial infections [17] . In such children, administration of IFN-~ was able to reverse a secondary defect of NK activity and permitted better control of infections [20] . Such observations, although made in rare patients, do indicate an immunoregulatory role for IFN in vivo. Better still, the association of a selection defect of 7-and ~-IFN secretion and a permanent, secondary defect of NK activity is compatible with the hypothesis that endogenous secretion of leukocyte interferons participates in the maintenance of a basic level (homeostasis) of activation of cells of the immune system, including NK cells and macrophages.
It should be stressed again that none of the above listed observations constitutes definitive evidence that inter-ferons participate in the regulation of the immune system. Yet this idea is so powerful and irresistible, even if not yet demonstrated, that it should prompt further research in this area. As one great French biologist used to write (( Aimer une idSe, c'est l'aimer un peu plus qu'on ne devrait )) (Jean Rostand, (c Carnet d'un biologiste ))). As far as the therapeutic implications of the hypothesis are concerned, another sentence from the same scientist applies: (( Attendre d'en savoir assez pour agir en toute lumi~re, c'est se condamner h l'inaction )) (Jean Rostand, (( In-quiStudes d'un biologiste ))).
Re[erences.
[1] FAUCONNIER, B., Augmentation de la pathogdnicit6 virale par l'emploi de sdrum anti- [4] SCOTT, G. M., Interferon: pharmacokinetics and toxicity. Phil. Trans. roy.
Soc. London, 1982, 299, 91.
[5] VAN 
